The intraocular use of bevacizumab for age-related macular degeneration was adopted by Chinese ophthalmologists in 2009.However,it was terminated after an outbreak of acute endophthalmitisn Shanghai.We discuss the reasons why this occurs and hope to convince Chinese regulators toeconsider their policies and allow the use of off-label bevacizumab with rigorous supervision.